Breast Neoplasms Clinical Trials in Grand Rapids, Michigan

4 studies are recruiting for breast neoplasms in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colore…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    BAMF Health Inc., Grand Rapids, Michigan
    Locations
    33 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07114601 on ClinicalTrials.gov

  2. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    BAMF Health Inc., Grand Rapids, Michigan
    Locations
    30 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07213791 on ClinicalTrials.gov

  3. Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

    The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test re…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Cancer & Hematology Centers, Grand Rapids, Michigan
    Locations
    49 in total
    Run by
    Natera, Inc.

    See if you can join NCT07214532 on ClinicalTrials.gov

  4. A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

    This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592,…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    GSK Investigational Site, Grand Rapids, Michigan
    Locations
    25 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT04641247 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.